Trial Profile
A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Mar 2022
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary) ; Ipilimumab
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 28 Mar 2021 This trial has been completed in Germany (Global End Date: 09 Mar 2021), according to European Clinical Trials Database record.
- 23 Mar 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results of post hoc analysis (As of February 25, 2019) evaluating Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab, presented at the 56th Annual Meeting of the American Society of Clinical Oncology